Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 58 min ago

IMMUNIC, INC.: ORBIMED ADVISORS LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Orbimed Advisors LLC amended its Schedule 13G filing on Immunic, Inc., disclosing a change in its passive stake in the company. The amendment was submitted to the SEC under accession number 0000947871-26-001032. Schedule 13G filings are used by investors holding stakes below the 20% threshold or by qualified institutional investors, and amendments typically signal a shift in position size or ownership status. The filing does not in itself indicate activist intent, as 13G is a passive-investment designation. Investors will watch for further 13G or 13D filings to gauge whether Orbimed's position in Immunic is increasing or being reduced.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

IMMUNIC, INC., ORBIMED ADVISORS LLC